Search Results | Showing 41 - 50 of 120 results for "Biotech" |
| | | ... chapter for TelstraSuper. We'll be supporting promising opportunities in the fields of healthcare, technology, cleantech and biotech based on scientific research and aiming to turn these into outstanding returns for our members," Miller said. "Unlike ... |
| | | | Lonsec's rating of Arnhem Investment Management's global separately managed account was upgraded in its latest round of reviews. Arnhem's global SMA, the Australia+ SMA, is now 'Recommended' by the ratings house, with Lonsec highlighting its "highly ... |
| | | | ... world market," Curnock Cook said. The BTF will be Australia's largest life sciences fund, with private investors including biotech company CSL Limited, AustralianSuper, HESTA, Statewide and Hostplus. The fund is expected to make its first investments ... |
| | | | ... than the long-term benefits of innovation. However, investment manager QIC says that the recent success of one of its biotech investments, Hatchtech, demonstrates the great potential of the market. Melbourne-based Hatchtech is the developer of a next ... |
| | | | ... with a focus on technology, including: M.H. Carnegie & Co (general and medical technology), Brandon Capital Partners (biotech), and Blackbird Ventures (software). |
| | | | ... said capital stewardship is not about an ESG or values-based overlay because that could be anybody's values. He cited biotech and genetic modification as an example where values-based investing becomes tricky. He said another example at Aberdeen was ... |
| | | | Sunsuper is welcoming two new board members this week and the appointments will form an integral part of a cultural and digital transformation at the $35 billion fund. Joining Sunsuper's board are Theresa Moltoni and Professor Mark Harvey. The pair ... |
| | | | The launch of a new ETF which exposes investors to the companies most talked about on social media proves index investing is limited only by product providers' imagination. The new product, launched on the NYSE by Toronto-based alternative fund manager ... |
| | | | Blue Sky Venture Capital has exited a head lice treatment company after it entered into a $278 million commercial agreement with Indian-based Dr. Reddy's Laboratories. Blue Sky invested in Hatchtech in 2013 as part of a $12 million syndicate of Australian ... |
| | | | The Australian market looks set to open lower after falls on Wall Street following a mixed batch of earnings reports and another big decline by technology giant Apple. At 0815 AEST on Wednesday, the September share price index futures contract was down ... |
|